2024 Drug-Induced Liver Injury Conference
Friday, 17 May in Washington, DC.
IQ DILI was delighted to host this informative and engaging conference planned by a partnership of experts from AASLD, FDA, NIH, CIOMS, and IQ DILI. The presentations (linked below) address the forms and mechanisms of hepatotoxicity connected to the wide range of new agents and how product-specific hepatotoxic risk can impact different clinical study and post-market treatment groups.
You can access the conference program packet here.
Contact IQ DILI Secretariat for additional information.
SESSION 1: CURRENT STATUS OF DILI IN THE US
Robert Fontana, University of Michigan
Jay Hoofnagle, National Institutes of Health
Victor Navarro, Jefferson Health
SESSION 2: IN VITRO & IN VIVO MODELS OF DILI & PATHOGENESIS
Mark Avigan, US Food and Drug Administration
Kyunghee Yang, QSP Solution, Simulations Plus
Guru Aithal, Nottingham Biomedical Research Centre
SESSION 3: PATHOGENESIS IN SPECIFIC FORMS OF DILI
Ikhlas Khan, University of Mississippi
Gina Choi, University of California,
Paul Watkins, University of North Carolina
Elizabeth Phillips, Vanderbilt University Medical Center
SESSION 4: IMMUNE-MEDIATED DILI
John Vierling, Baylor College of Medicine
Lily Dara, University of Southern California
K.Rajender Reddy, University of Pennsylvania